Elgart, Anna
Zur, Arik A.
Mimrod, Dorit
Dror, Vered
Bar-Ilan, Oren
Korver, Tjeerd
Spiegelstein, Ofer
Funding for this research was provided by:
Teva Pharmaceutical Industries
Article History
Received: 13 May 2018
Accepted: 28 August 2018
First Online: 6 September 2018
Compliance with ethical standards
:
: Authors AE, AZ, DM, VD, OBI and OS are employees of Teva Pharmaceuticals Ltd. who are sponsoring the clinical development of laquinimod for Huntington’s disease. TK was a consultant for Teva Pharmaceutics at the time the study was conducted.
: The study was carried out in compliance with the Declaration of Helsinki and International Council on Harmonization (ICH) Good Clinical Practice (E6) Guidelines and applicable national and local laws and regulations. The study was initiated after receiving approval from Independent Ethics Committee (IEC) Ethikkommission der Ärztekammer Nordrhein, Düsseldorf Germany, and from national or local regulations of the competent health authorities. All the subjects gave their written consent for voluntary participation.